|
Ed Hurwitz joined Alta Partners in 2002 and is a Director in Alta BioPharma III and Alta Partners VIII. In addition to Cara Therapeutics Inc. Ed serves on the Board of Directors of FoldRx, and MacroGenics, and led Alta’s investments in ChemoCentryx, Threshold Pharmaceuticals and Sunesis. From 1997 to 2002, Ed was Senior Vice President and Chief Financial Officer of Affymetrix. From 1994 to 1997, Ed was a biotechnology research analyst for Robertson Stephens & Company and, from 1992 to 1994, served a similar role for Smith Barney Shearson. From 1990 to 1992, Ed practiced commercial law at Cooley Godward LLP. Ed earned his Juris Doctor (JD) and Master of Business Administration degrees in 1990 from the University of California, Berkeley’s Boalt School of Law and Haas School of Business, respectively. Ed earned a Bachelor of Arts in Molecular Biology from Cornell University in 1985 | 